Kilewo C, Massawe A, Lyamuya E, Semali I, Kalokola F, Urassa E, Giattas M, Temu F, Karlsson K, Mhalu F, Biberfeld G
Department of Obstetrics and Gynaecology, Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania.
J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):458-62. doi: 10.1097/00042560-200112150-00009.
The aim of this study was to determine the acceptability of HIV counseling and testing and participation in a mother-to-child HIV-1 transmission intervention study using antiretroviral therapy in Dar es Salaam, Tanzania, one of the sites for the Joint United Nations Program on AIDS (UNAIDS) multicenter Petra trial. HIV testing was offered to all pregnant women who visited three prenatal clinics in Dar es Salaam before 34 weeks' gestation. Group or individual pretest counseling was performed by trained midwives. Laboratory diagnosis of HIV infection was based on two sequential anti-HIV enzyme-linked immunosorbent assays. Posttest counseling was given 2 weeks later to women who wished to know their HIV status. HIV testing was offered to a total of 10,010 pregnant women from June 1996 to May 1998, of whom 76.4% (7647 of 10,010) agreed to be tested. The prevalence of HIV-1 infection was 13.7% (1050 of 7647). Overall, 68.1% (5205 of 7647) returned for their results. Of the HIV-1-seropositive respondents, 27.4% (288 of 1050) agreed to participate in the Petra trial after fulfilling the eligibility criteria. Only 16.7% (48 of 288) of the enrolled women disclosed their positive HIV serostatus to their sexual partners. The main reasons for not disclosing the HIV serostatus were fear of stigma and divorce. Sixty percent (29 of 48) of the informed sex partners agreed to be tested for HIV and 69% (20 of 29) tested HIV seropositive. Pregnancy recurrence rate was 4.4 per 100 women years (18 pregnancies during 408 women years of follow-up) with 10 of 18 (55.6%) women not wanting to carry the pregnancy to term. In conclusion, this information is useful in planning intervention programs for prevention of mother-to-child HIV-1 transmission and it shows that improvements are required in counseling.
本研究的目的是确定在坦桑尼亚达累斯萨拉姆开展的一项使用抗逆转录病毒疗法预防母婴HIV-1传播干预研究中,HIV咨询与检测的可接受性以及参与情况。达累斯萨拉姆是联合国艾滋病规划署(UNAIDS)多中心佩特拉试验的地点之一。对所有在妊娠34周前到过达累斯萨拉姆三家产前诊所就诊的孕妇提供HIV检测。由经过培训的助产士进行小组或个体检测前咨询。HIV感染的实验室诊断基于连续两次抗HIV酶联免疫吸附试验。检测2周后,为希望了解自身HIV状况的女性提供检测后咨询。1996年6月至1998年5月,共向10010名孕妇提供了HIV检测,其中76.4%(10010人中的7647人)同意接受检测。HIV-1感染率为13.7%(7647人中的1050人)。总体而言,68.1%(7647人中的5205人)返回获取检测结果。在HIV-1血清学阳性的应答者中,27.4%(1050人中的288人)在符合入选标准后同意参与佩特拉试验。在登记参与试验的女性中,只有16.7%(288人中的48人)向其性伴侣披露了自己HIV血清学阳性状态。未披露HIV血清学状态的主要原因是害怕耻辱和离婚。60%(48人中的29人)知晓情况的性伴侣同意接受HIV检测,其中69%(29人中的20人)检测为HIV血清学阳性。妊娠复发率为每100妇女年4.4次(408妇女年随访期间有18次妊娠),18名妇女中有10名(55.6%)不想将妊娠维持至足月。总之,这些信息对规划预防母婴HIV-1传播的干预项目很有用,并且表明咨询工作需要改进。